TAS 102

Phase 3Small molecule

TAS 102 is one of 383 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

382

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Colon AdenocarcinomaActive, not recruiting

Gastric AdenocarcinomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Squamous Cell Lung CarcinomaActive, not recruiting

Esophageal AdenocarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 3

Active, not recruiting

Colorectal CarcinomaPhase 2/Phase 3

Active, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Colon AdenocarcinomaPhase 1

Active, not recruiting

Gastric AdenocarcinomaPreclinical

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Squamous Cell Lung CarcinomaPhase 2

Active, not recruiting

Esophageal AdenocarcinomaPhase 1

Active, not recruiting

Metastatic Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Pancreatic AdenocarcinomaPhase 2

Active, not recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

TAS 102

Taiho Oncology, Inc.

Phase 3

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

MS Contin

Merck & Co.

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

ABI-007

Bristol-Myers Squibb

Preclinical

2 7

LDE225

Novartis

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Thiazolidinediones

Sanofi

Preclinical

1 10

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Gastric Cancer

NCT06346392

Phase 1Recruiting

Colon Adenocarcinoma

NCT04920032

Q2 2027

Phase 2Recruiting

Colorectal Cancer

NCT05343013

Q4 2028

Phase 2Not yet recruiting

Radiotherapy

NCT07116577

Phase 1/2Not yet recruiting

Radiotherapy

NCT07196345

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer10 trials

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT05328908·770 enrolled

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 3·NCT01607957·800 enrolled

Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT05266820·120 enrolled

Show 7 more trials

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Approved for marketing· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.··NCT02286492

Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Unknown status·HHoly Stone Healthcare Co., Ltd·Phase 2·NCT06039202·100 enrolled

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT01896856·118 enrolled

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 3·NCT03520946·430 enrolled

Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

Completed·AAIO-Studien-gGmbH·Phase 1·NCT03305913·12 enrolled

Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia

Completed· Taiho Pharmaceutical Co., Ltd. logo

Taiho Pharmaceutical Co., Ltd.·Phase 3·NCT01955837·406 enrolled

Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer

Terminated·GGeorgetown University·Phase 2·NCT02654639·4 enrolled

Colorectal Cancer7 trials

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT05600309·94 enrolled

Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

Completed· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT03974594·64 enrolled

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT05314101·25 enrolled

Show 4 more trials

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer

Completed·MMassachusetts General Hospital·Phase 1/2·NCT03223779·52 enrolled

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05343013·25 enrolled

Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04683965·27 enrolled

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT05064059·441 enrolled

Patients With Advanced Solid Tumors3 trials

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 1·NCT02301117·43 enrolled

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 1·NCT02301104·24 enrolled

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 1·NCT01867879·44 enrolled

Gastric Cancer2 trials

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 3·NCT02500043·507 enrolled

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06346392·594 enrolled

Pancreatic Adenocarcinoma2 trials

TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

Completed·TThe University of Hong Kong·Phase 2·NCT04923529·28 enrolled

TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)

Terminated·UUniversity of Florida·Phase 2·NCT02921737·7 enrolled

21 more indications

Adenocarcinoma2 trials

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03686488·23 enrolled

iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Completed·AAHS Cancer Control Alberta·Phase 2·NCT04808791·7 enrolled

mCRC2 trials

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Active, not recruiting·UUniversity of California, Irvine·Phase 1·NCT04868773·12 enrolled

Sym004 Versus TAS-102 in Patients With mCRC

Withdrawn·SSymphogen A/S·Phase 3·NCT03717038

Radiotherapy2 trials

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Not yet recruiting·—·Phase 2·NCT07116577·37 enrolled

TAS-102 Plus Radiotherapy in Elderly ESCC

Not yet recruiting·QQianfoshan Hospital·Phase 1/2·NCT07196345·45 enrolled

Pancreatic Cancer1 trial

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Completed·SSun Yat-sen University·Phase 2·NCT05481463·22 enrolled

Esophageal Adenocarcinoma1 trial

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Completed·UUniversity of California, Irvine·Phase 1·NCT04074343·20 enrolled

Gastric Adenocarcinoma1 trial

Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·N/A·NCT04517747·20 enrolled

Colorectal Carcinoma1 trial

Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

Unknown status·AAmsterdam UMC, location VUmc·Phase 2/3·NCT03909724·60 enrolled

Bladder Cancer1 trial

A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

Unknown status·RRahul Parikh·Phase 2·NCT03762161·22 enrolled

Gastrointestinal Tumors1 trial

A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 1·NCT01916447·65 enrolled

Temozolomide1 trial

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

Terminated·UUniversity of Wisconsin, Madison·Phase 1·NCT02943733·18 enrolled

Nasopharyngeal Carcinoma1 trial

A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown status·NNational University Hospital, Singapore·Phase 2·NCT04627961·33 enrolled

Anlotinib1 trial

TAS-102 and Anlotinib in ≥3 Lines mGC

Unknown status·ZZhejiang University·Phase 2·NCT05029102·45 enrolled

Tics1 trial

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 1·NCT01867866·44 enrolled

Rectal Cancer1 trial

SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer

Completed·PProvidence Health & Services·Phase 2·NCT04417699·13 enrolled

Nivolumab1 trial

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 2·NCT02860546·18 enrolled

Small Cell Lung Cancer1 trial

A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

Terminated· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 2·NCT01904253·18 enrolled

Colon Adenocarcinoma1 trial

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Recruiting·UUniversity of California, Irvine·Phase 1·NCT04920032·22 enrolled

Solid Tumors1 trial

A Phase I Study of TAS-102 in Solid Tumors

Completed· Taiho Pharmaceutical Co., Ltd. logo

Taiho Pharmaceutical Co., Ltd.·Phase 1·NCT02261532·15 enrolled

Liver Metastases1 trial

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Completed·UUniversity of California, San Francisco·Phase 1·NCT02602327·21 enrolled

Squamous Cell Lung Carcinoma1 trial

TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)

Completed·UUniversity of Florida·Phase 2·NCT02920476·4 enrolled

Unspecified1 trial

AB122 Platform Study

Recruiting· Taiho Pharmaceutical Co., Ltd. logo

Taiho Pharmaceutical Co., Ltd.·Phase 1·NCT04999761·917 enrolled

Sources

References

[1]
ClinicalTrials.gov — 48 trial records for TAS 102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAS 102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAS 102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taiho Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Taiho Oncology, Inc.

TAS 102

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2028

Trials by Indication[1]

Metastatic Colorectal Cancer10 trials

Colorectal Cancer7 trials

Patients With Advanced Solid Tumors3 trials

Gastric Cancer2 trials

Pancreatic Adenocarcinoma2 trials

Adenocarcinoma2 trials

mCRC2 trials

Radiotherapy2 trials

Pancreatic Cancer1 trial

Esophageal Adenocarcinoma1 trial

Gastric Adenocarcinoma1 trial

Colorectal Carcinoma1 trial

Bladder Cancer1 trial

Gastrointestinal Tumors1 trial

Temozolomide1 trial

Nasopharyngeal Carcinoma1 trial

Anlotinib1 trial

Tics1 trial

Rectal Cancer1 trial

Nivolumab1 trial

Small Cell Lung Cancer1 trial

Colon Adenocarcinoma1 trial

Solid Tumors1 trial

Liver Metastases1 trial

Squamous Cell Lung Carcinoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News